Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Feb 1;13(2):2.
doi: 10.1167/tvst.13.2.2.

Predicting the Extent of Damage in the Humphrey Field Analyzer 24-2 Visual Fields Using 10-2 Test Results in Patients With Advanced Glaucoma

Ryo Asaoka  1   2   3   4 , Kenji Sugisaki  5   6 , Toshihiro Inoue  7 , Keiji Yoshikawa  8 , Akiyasu Kanamori  9 , Yoshio Yamazaki  10 , Shinichiro Ishikawa  11 , Kenichi Uchida  12 , Aiko Iwase  13 , Makoto Araie  6   14 ; for Advanced Glaucoma Study Members in Japan Glaucoma Society
Affiliations

Predicting the Extent of Damage in the Humphrey Field Analyzer 24-2 Visual Fields Using 10-2 Test Results in Patients With Advanced Glaucoma

Ryo Asaoka et al. Transl Vis Sci Technol. .

Abstract

Purpose: To predict Humphrey Field Analyzer 24-2 test (HFA 24-2) results using 10-2 results.

Methods: A total of 175 advanced glaucoma eyes (175 patients) with HFA 24-2 mean deviation (MD24-2) of < -20 dB were prospectively followed up for five years using HFA 10-2 and 24-2 (twice and once in a year, respectively). Using all the HFA 24-2 and 10-2 test result pairs measured within three months (350 pairs from 85 eyes, training dataset), a formula to predict HFA 24-2 result using HFA 10-2 results was constructed using least absolute shrinkage and selection operator regression (LASSO). Using 90 different eyes (testing dataset), the absolute differences between the actual and LASSO-predicted MD24-2 and that between the slopes calculated using five actual and LASSO-predicted MD24-2 values, were adopted as the prediction error. Similar analyses were performed for the mean total deviation values (mTD) of the superior (or inferior) hemifield [hemi-mTDsup.24-2(-hemi-mTDinf.24-2)].

Results: The prediction error for the LASSO-predicted MD24-2 and its slope were 2.98 (standard deviation [SD] = 1.90) dB and 0.32 (0.33) dB/yr, respectively. The LASSO-predicted hemi-mTDsup.24-2 (hemi-mTDinf.24-2), and its slope were 3.02 (2.89) and 3.76 (2.72) dB, and 0.37 (0.41) and 0.44 (0.38) dB/year, respectively. These prediction errors were within two times SD of repeatability of the simulated stable HFA 24-2 VF parameter series.

Conclusions: HFA 24-2 results could be predicted using the paired HFA 10-2 results with reasonable accuracy using LASSO in patients with advanced glaucoma.

Translational relevance: It is useful to predict HFA24-2 test from HFA10-2 test, when the former is not available, in advanced glaucoma.

PubMed Disclaimer

Conflict of interest statement

Disclosure: R. Asaoka, Oculus (I), Reichert (I), Nidek (I), Kowa (I); K. Sugisaki, Japan Glaucoma Society (R), Senju Pharmaceutical (I), Kowa (I), Alcon Japan (I); T. Inoue, Kowa (R, I), Novartis Pharma (R, I), Senju Pharmaceutical (R, I), Pfizer Japan (R, I), Otsuka Pharmaceutical (R, I), Tomey (I), Santen Pharmaceutical (I), Japan Focus Company (I), Beyer (I), Glaukos (I), Wakamoto Pharmaceutical (I), Mitsubishi Tanabe Pharma (I), Allergan (I), Alcon Japan (R); K. Yoshikawa, Santen Pharmaceutical (I), Senju Pharmaceutical (I), Otsuka Pharmaceutical (I), CREWT Medical Systems (I), JFC Sales Plan (I), R E Medical (I); A. Kanamori, Santen Pharmaceutical Co. (I), Otsuka Pharmaceutical Co. (I), Senjyu Pharmaceutical Co. (I), Kowa Pharmaceutical Co. (I), Nitten Pharmaceutical Co. (I); Y. Yamazaki, Kowa (I), Santen Pharmaceutical (I), Senju Pharmaceutical (I), Novaritis Pharma (I); S. Ishikawa, Santen (I), Senjyu (I), Kowa (I), Otuka (I), Alcon (I), Seed (I), Nitten (I); K. Uchida, None; A. Iwase, Carl Zeiss Meditec (I), Kowa (I), Otsuka (I), Pfizer (I), Santen (I), Senju (I), Novartis (I), JGSTK-DiscAnalysis (P); M. Araie, Pfizer (I), Santen Pharmacy (I), Topcon Medical System (I), Otsuka (I), Senju (I), Aerie (I), Kowa (I), JGSTK-DiscAnalysis (S)

Figures

Figure.
Figure.
The AUC for detecting a progression of <−1.0 dB/year (P < 0.05) in the actual MD24-2, hemi-mTDsup.24-2, or hemi-mTDinf.24-2 slope using the LASSO-predicted MD24-2 slope. The AUC was 0.93 (95% CI = 0.86 to 0.97) with an optimum sensitivity and specificity of 100.0% and 84.0%, respectively.
See this image and copyright information in PMC

Similar articles

See all similar articles

References

    1. Quigley HA, Broman AT.. The number of people with glaucoma worldwide in 2010 and 2020. Br J Ophthalmol. 2006; 90: 262–267. - PMC - PubMed
    1. Aulhorn E., Harms H.. Early visual field defects in glaucoma. In: Leydheeker W, ed. Glaucoma Symposion Tutziug Castle 1966 . New York: Karger; 1967: 151–186.
    1. Aulhorn E, Karmeyer H.. Frequency distribution in early glaucomatous visual field defects. In: Greve EL, ed. Second International Visual Field Symposium Tubingen 1976. Den Haag: Junk; 1977: 75–83.
    1. Weber J, Schultze T, Ulrich H.. The visual field in advanced glaucoma. Int Ophthalmol. 1989; 13: 47–50. - PubMed
    1. Zalta AH. Use of a central 10 degrees field and size V stimulus to evaluate and monitor small central islands of vision in end stage glaucoma. Br J Ophthalmol. 1991; 75: 151–154. - PMC - PubMed